25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Imugene Ltd
Buy, Hold or Sell?

Let's analyze Imugene together

I guess you are interested in Imugene Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Imugene Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Imugene Ltd

I send you an email if I find something interesting about Imugene Ltd.

1. Quick Overview

1.1. Quick analysis of Imugene (30 sec.)










1.2. What can you expect buying and holding a share of Imugene? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
A$0.02
Expected worth in 1 year
A$-0.02
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
A$-0.04
Return On Investment
-85.7%

For what price can you sell your share?

Current Price per Share
A$0.04
Expected price per share
A$0.039 - A$0.048
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Imugene (5 min.)




Live pricePrice per Share (EOD)
A$0.04
Intrinsic Value Per Share
A$-0.20 - A$-0.09
Total Value Per Share
A$-0.18 - A$-0.07

2.2. Growth of Imugene (5 min.)




Is Imugene growing?

Current yearPrevious yearGrowGrow %
How rich?$77.8m$124.8m-$47m-60.4%

How much money is Imugene making?

Current yearPrevious yearGrowGrow %
Making money-$98.5m-$24.9m-$73.6m-74.7%
Net Profit Margin0.0%-321.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Imugene (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#399 / 958

Most Revenue
#800 / 958

Most Profit
#918 / 958

Most Efficient
#182 / 958
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Imugene?

Welcome investor! Imugene's management wants to use your money to grow the business. In return you get a share of Imugene.

First you should know what it really means to hold a share of Imugene. And how you can make/lose money.

Speculation

The Price per Share of Imugene is A$0.044. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Imugene.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Imugene, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.02. Based on the TTM, the Book Value Change Per Share is A$-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Imugene.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.01-29.6%-0.01-29.6%0.00-7.5%0.00-10.1%0.00-5.4%
Usd Book Value Change Per Share-0.01-14.1%-0.01-14.1%0.0010.1%0.003.6%0.002.2%
Usd Dividend Per Share0.000.0%0.000.0%0.0115.4%0.004.9%0.002.4%
Usd Total Gains Per Share-0.01-14.1%-0.01-14.1%0.0125.5%0.008.5%0.004.6%
Usd Price Per Share0.04-0.04-0.06-0.09-0.05-
Price to Earnings Ratio-2.88--2.88--18.16--44.98--39.39-
Price-to-Total Gains Ratio-6.04--6.04-5.34-27.37-79.31-
Price to Book Ratio3.65-3.65-3.63-12.47-10.85-
Price-to-Total Gains Ratio-6.04--6.04-5.34-27.37-79.31-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0289784
Number of shares34508
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share-0.010.00
Gains per Quarter (34508 shares)-214.36128.39
Gains per Year (34508 shares)-857.43513.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-857-867295219504
20-1715-17245904371018
30-2572-25818856561532
40-3430-343811808742046
50-4287-4295147510932560
60-5145-5152177013113074
70-6002-6009206515303588
80-6859-6866236017484102
90-7717-7723265519674616
100-8574-8580295021865130

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%4.028.00.012.5%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%9.01.00.090.0%18.014.00.056.3%
Dividend per Share0.00.01.00.0%2.00.01.066.7%4.00.01.080.0%4.00.06.040.0%4.00.028.012.5%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%9.01.00.090.0%18.014.00.056.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Imugene Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.009-0.0090%0.007-240%0.002-492%0.001-740%
Book Value Per Share--0.0160.0160%0.025-38%0.015+3%0.008+84%
Current Ratio--3.8583.8580%27.229-86%13.291-71%12.944-70%
Debt To Asset Ratio--0.2190.2190%0.038+480%0.099+121%0.112+95%
Debt To Equity Ratio--0.2800.2800%0.039+615%0.116+142%0.130+115%
Dividend Per Share----0%0.010-100%0.003-100%0.002-100%
Eps---0.020-0.0200%-0.005-75%-0.007-66%-0.004-82%
Free Cash Flow Per Share---0.014-0.0140%-0.004-72%-0.005-63%-0.003-80%
Free Cash Flow To Equity Per Share---0.008-0.0080%0.007-208%0.002-473%0.001-706%
Gross Profit Margin--1.0001.0000%1.013-1%1.008-1%1.064-6%
Intrinsic Value_10Y_max---0.087--------
Intrinsic Value_10Y_min---0.198--------
Intrinsic Value_1Y_max---0.004--------
Intrinsic Value_1Y_min---0.011--------
Intrinsic Value_3Y_max---0.016--------
Intrinsic Value_3Y_min---0.040--------
Intrinsic Value_5Y_max---0.032--------
Intrinsic Value_5Y_min---0.078--------
Market Cap332951517.184-30%431323556.352431323556.3520%688604274.176-37%1080579014.861-60%599085718.533-28%
Net Profit Margin----0%-3.2190%-2.2470%-2.2970%
Operating Margin----0%-4.3550%-3.0820%-3.5050%
Operating Ratio----0%4.355-100%3.082-100%3.196-100%
Pb Ratio2.816-30%3.6473.6470%3.631+0%12.468-71%10.846-66%
Pe Ratio-2.224+23%-2.882-2.8820%-18.162+530%-44.979+1461%-39.390+1267%
Price Per Share0.044-30%0.0570.0570%0.091-37%0.143-60%0.079-28%
Price To Free Cash Flow Ratio-3.118+23%-4.039-4.0390%-23.124+472%-47.200+1068%-39.150+869%
Price To Total Gains Ratio-4.665+23%-6.043-6.0430%5.344-213%27.367-122%79.310-108%
Quick Ratio--3.6583.6580%27.163-87%13.187-72%12.714-71%
Return On Assets---0.989-0.9890%-0.192-81%-0.371-62%-0.309-69%
Return On Equity---1.266-1.2660%-0.200-84%-0.440-65%-0.362-71%
Total Gains Per Share---0.009-0.0090%0.017-155%0.006-267%0.003-405%
Usd Book Value--77882352.45077882352.4500%124887684.917-38%75266027.991+3%42226970.812+84%
Usd Book Value Change Per Share---0.006-0.0060%0.004-240%0.002-492%0.001-740%
Usd Book Value Per Share--0.0100.0100%0.017-38%0.010+3%0.006+84%
Usd Dividend Per Share----0%0.007-100%0.002-100%0.001-100%
Usd Eps---0.013-0.0130%-0.003-75%-0.004-66%-0.002-82%
Usd Free Cash Flow---70323942.722-70323942.7220%-19612258.406-72%-26038218.079-63%-14388019.611-80%
Usd Free Cash Flow Per Share---0.009-0.0090%-0.003-72%-0.003-63%-0.002-80%
Usd Free Cash Flow To Equity Per Share---0.005-0.0050%0.005-208%0.001-473%0.001-706%
Usd Market Cap219281869.217-30%284069694.213284069694.2130%453514774.972-37%711669339.187-60%394557854.226-28%
Usd Price Per Share0.029-30%0.0380.0380%0.060-37%0.094-60%0.052-28%
Usd Profit---98579602.985-98579602.9850%-24970746.554-75%-33513251.550-66%-18033453.792-82%
Usd Revenue----0%7756745.801-100%4756790.793-100%2993202.646-100%
Usd Total Gains Per Share---0.006-0.0060%0.011-155%0.004-267%0.002-405%
 EOD+3 -5MRQTTM+0 -0YOY+2 -325Y+6 -2810Y+6 -28

3.3 Fundamental Score

Let's check the fundamental score of Imugene Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.224
Price to Book Ratio (EOD)Between0-12.816
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.658
Current Ratio (MRQ)Greater than13.858
Debt to Asset Ratio (MRQ)Less than10.219
Debt to Equity Ratio (MRQ)Less than10.280
Return on Equity (MRQ)Greater than0.15-1.266
Return on Assets (MRQ)Greater than0.05-0.989
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Imugene Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.045
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Imugene Ltd

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.

Fundamental data was last updated by Penke on 2024-10-23 13:40:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Imugene earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Imugene to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Imugene Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-321.9%+321.9%
TTM-5Y-224.7%+224.7%
5Y-224.7%10Y-229.7%+5.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--135.5%+135.5%
TTM--205.3%+205.3%
YOY-321.9%-207.5%-114.4%
5Y-224.7%-353.5%+128.8%
10Y-229.7%-464.5%+234.8%
4.3.1.2. Return on Assets

Shows how efficient Imugene is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Imugene to the Biotechnology industry mean.
  • -98.9% Return on Assets means that Imugene generated $-0.99 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Imugene Ltd:

  • The MRQ is -98.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -98.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-98.9%TTM-98.9%0.0%
TTM-98.9%YOY-19.2%-79.6%
TTM-98.9%5Y-37.1%-61.8%
5Y-37.1%10Y-30.9%-6.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-98.9%-10.9%-88.0%
TTM-98.9%-11.8%-87.1%
YOY-19.2%-11.1%-8.1%
5Y-37.1%-12.7%-24.4%
10Y-30.9%-14.3%-16.6%
4.3.1.3. Return on Equity

Shows how efficient Imugene is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Imugene to the Biotechnology industry mean.
  • -126.6% Return on Equity means Imugene generated $-1.27 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Imugene Ltd:

  • The MRQ is -126.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -126.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-126.6%TTM-126.6%0.0%
TTM-126.6%YOY-20.0%-106.6%
TTM-126.6%5Y-44.0%-82.6%
5Y-44.0%10Y-36.2%-7.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-126.6%-13.7%-112.9%
TTM-126.6%-16.0%-110.6%
YOY-20.0%-13.5%-6.5%
5Y-44.0%-18.5%-25.5%
10Y-36.2%-19.0%-17.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Imugene Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Imugene is operating .

  • Measures how much profit Imugene makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Imugene to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Imugene Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-435.5%+435.5%
TTM-5Y-308.2%+308.2%
5Y-308.2%10Y-350.5%+42.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.0%+286.0%
TTM--313.4%+313.4%
YOY-435.5%-222.8%-212.7%
5Y-308.2%-385.5%+77.3%
10Y-350.5%-494.6%+144.1%
4.3.2.2. Operating Ratio

Measures how efficient Imugene is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Imugene Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY4.355-4.355
TTM-5Y3.082-3.082
5Y3.08210Y3.196-0.114
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.842-2.842
TTM-3.179-3.179
YOY4.3553.300+1.055
5Y3.0824.823-1.741
10Y3.1966.520-3.324
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Imugene Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Imugene is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.86 means the company has $3.86 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Imugene Ltd:

  • The MRQ is 3.858. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.858. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.858TTM3.8580.000
TTM3.858YOY27.229-23.371
TTM3.8585Y13.291-9.433
5Y13.29110Y12.944+0.347
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8583.747+0.111
TTM3.8583.923-0.065
YOY27.2294.715+22.514
5Y13.2915.960+7.331
10Y12.9446.291+6.653
4.4.3.2. Quick Ratio

Measures if Imugene is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Imugene to the Biotechnology industry mean.
  • A Quick Ratio of 3.66 means the company can pay off $3.66 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Imugene Ltd:

  • The MRQ is 3.658. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.658. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.658TTM3.6580.000
TTM3.658YOY27.163-23.505
TTM3.6585Y13.187-9.529
5Y13.18710Y12.714+0.473
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.6583.342+0.316
TTM3.6583.522+0.136
YOY27.1634.658+22.505
5Y13.1875.922+7.265
10Y12.7146.478+6.236
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Imugene Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Imugene assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Imugene to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.22 means that Imugene assets are financed with 21.9% credit (debt) and the remaining percentage (100% - 21.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Imugene Ltd:

  • The MRQ is 0.219. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.219. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.219TTM0.2190.000
TTM0.219YOY0.038+0.181
TTM0.2195Y0.099+0.120
5Y0.09910Y0.112-0.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2190.338-0.119
TTM0.2190.346-0.127
YOY0.0380.308-0.270
5Y0.0990.365-0.266
10Y0.1120.379-0.267
4.5.4.2. Debt to Equity Ratio

Measures if Imugene is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Imugene to the Biotechnology industry mean.
  • A Debt to Equity ratio of 28.0% means that company has $0.28 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Imugene Ltd:

  • The MRQ is 0.280. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.280. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.280TTM0.2800.000
TTM0.280YOY0.039+0.241
TTM0.2805Y0.116+0.165
5Y0.11610Y0.130-0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2800.392-0.112
TTM0.2800.439-0.159
YOY0.0390.375-0.336
5Y0.1160.450-0.334
10Y0.1300.488-0.358
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Imugene generates.

  • Above 15 is considered overpriced but always compare Imugene to the Biotechnology industry mean.
  • A PE ratio of -2.88 means the investor is paying $-2.88 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Imugene Ltd:

  • The EOD is -2.224. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.882. Based on the earnings, the company is expensive. -2
  • The TTM is -2.882. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.224MRQ-2.882+0.657
MRQ-2.882TTM-2.8820.000
TTM-2.882YOY-18.162+15.280
TTM-2.8825Y-44.979+42.097
5Y-44.97910Y-39.390-5.589
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.224-2.326+0.102
MRQ-2.882-2.468-0.414
TTM-2.882-2.987+0.105
YOY-18.162-3.444-14.718
5Y-44.979-5.905-39.074
10Y-39.390-6.278-33.112
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Imugene Ltd:

  • The EOD is -3.118. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.039. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.039. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.118MRQ-4.039+0.921
MRQ-4.039TTM-4.0390.000
TTM-4.039YOY-23.124+19.085
TTM-4.0395Y-47.200+43.161
5Y-47.20010Y-39.150-8.050
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.118-3.181+0.063
MRQ-4.039-3.267-0.772
TTM-4.039-3.527-0.512
YOY-23.124-4.590-18.534
5Y-47.200-8.076-39.124
10Y-39.150-8.938-30.212
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Imugene is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.65 means the investor is paying $3.65 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Imugene Ltd:

  • The EOD is 2.816. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.647. Based on the equity, the company is fair priced.
  • The TTM is 3.647. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.816MRQ3.647-0.832
MRQ3.647TTM3.6470.000
TTM3.647YOY3.631+0.016
TTM3.6475Y12.468-8.820
5Y12.46810Y10.846+1.621
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.8161.931+0.885
MRQ3.6471.982+1.665
TTM3.6472.197+1.450
YOY3.6312.400+1.231
5Y12.4683.585+8.883
10Y10.8464.208+6.638
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Imugene Ltd.

4.8.2. Funds holding Imugene Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2021-01-31DFA International Sustainability Core 1 Portfolio0.029999999-1293602--
Total 0.0299999990129360200.0%
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-06-302021-06-302022-06-302023-06-302024-06-30
Gross Profit  4,0511,2185,2695,29310,563-9899,574-15,414-5,840



5.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets151,398
Total Liabilities33,143
Total Stockholder Equity118,254
 As reported
Total Liabilities 33,143
Total Stockholder Equity+ 118,254
Total Assets = 151,398

Assets

Total Assets151,398
Total Current Assets113,034
Long-term Assets38,364
Total Current Assets
Cash And Cash Equivalents 93,108
Short-term Investments 1,435
Net Receivables 12,619
Other Current Assets 7,308
Total Current Assets  (as reported)113,034
Total Current Assets  (calculated)114,469
+/- 1,435
Long-term Assets
Property Plant Equipment 1,699
Long Term Investments 2,413
Intangible Assets 34,120
Long-term Assets Other 133
Long-term Assets  (as reported)38,364
Long-term Assets  (calculated)38,364
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities29,299
Long-term Liabilities3,845
Total Stockholder Equity118,254
Total Current Liabilities
Short-term Debt 912
Accounts payable 5,968
Other Current Liabilities 22,418
Total Current Liabilities  (as reported)29,299
Total Current Liabilities  (calculated)29,299
+/-0
Long-term Liabilities
Long-term Liabilities Other 3,843
Long-term Liabilities  (as reported)3,845
Long-term Liabilities  (calculated)3,843
+/- 2
Total Stockholder Equity
Common Stock370,313
Retained Earnings -289,832
Accumulated Other Comprehensive Income 37,773
Total Stockholder Equity (as reported)118,254
Total Stockholder Equity (calculated)118,254
+/-0
Other
Capital Stock370,313
Cash and Short Term Investments 93,108
Common Stock Shares Outstanding 7,088,808
Liabilities and Stockholders Equity 151,398
Net Debt -91,561
Net Invested Capital 118,254
Net Working Capital 83,735
Property Plant and Equipment Gross 2,625
Short Long Term Debt Total 1,547



5.3. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-301998-06-301997-06-301996-06-301995-06-301994-06-301993-06-30
> Total Assets 
5,698
11,313
11,926
9,249
8,693
7,891
6,893
3,682
2,441
844
8,144
6,016
9,064
7,268
5,260
5,163
5,763
4,099
4,687
1,318
2,584
8,631
9,115
9,536
12,678
16,914
30,779
65,205
71,809
147,606
197,063
151,398
151,398197,063147,60671,80965,20530,77916,91412,6789,5369,1158,6312,5841,3184,6874,0995,7635,1635,2607,2689,0646,0168,1448442,4413,6826,8937,8918,6939,24911,92611,3135,698
   > Total Current Assets 
166
5,984
2,019
1,516
3,145
2,962
2,483
795
264
827
2,663
1,350
4,743
3,281
1,626
1,870
2,818
1,494
2,425
1,318
619
1,758
2,515
2,913
6,054
9,833
23,424
34,495
36,319
113,766
165,658
113,034
113,034165,658113,76636,31934,49523,4249,8336,0542,9132,5151,7586191,3182,4251,4942,8181,8701,6263,2814,7431,3502,6638272647952,4832,9623,1451,5162,0195,984166
       Cash And Cash Equivalents 
18
5,558
251
-689
2,035
1,814
2,108
402
29
783
2,618
963
4,346
2,697
1,099
1,620
2,487
793
1,906
1,017
566
1,223
1,957
1,583
4,814
7,822
19,048
30,107
29,487
99,888
153,151
93,108
93,108153,15199,88829,48730,10719,0487,8224,8141,5831,9571,2235661,0171,9067932,4871,6201,0992,6974,3469632,618783294022,1081,8142,035-6892515,55818
       Short-term Investments 
0
0
460
387
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,435
1,43500000000000000000000000000038746000
       Net Receivables 
148
73
193
45
126
666
144
129
61
44
39
385
391
41
1
61
41
181
53
267
54
8
2
1,313
1,220
1,915
4,215
4,194
6,662
12,768
12,105
12,619
12,61912,10512,7686,6624,1944,2151,9151,2201,31328542675318141611413913853944611291446661264519373148
       Other Current Assets 
0
0
0
0
0
0
0
102
0
0
45
75
110
542
525
190
290
520
466
267
6
526
556
1,331
1,240
2,011
4,376
194
170
1,110
402
7,308
7,3084021,1101701944,3762,0111,2401,33155652662674665202901905255421107545001020000000
   > Long-term Assets 
5,532
5,329
9,907
7,733
5,548
4,929
4,410
2,887
2,176
18
5,481
4,666
4,321
3,988
3,634
3,293
2,945
2,605
2,262
1
1,965
6,874
6,600
6,623
6,623
7,081
7,340
30,710
35,490
33,840
31,405
38,364
38,36431,40533,84035,49030,7107,3407,0816,6236,6236,6006,8741,96512,2622,6052,9453,2933,6343,9884,3214,6665,481182,1762,8874,4104,9295,5487,7339,9075,3295,532
       Property Plant Equipment 
28
449
2,522
2,326
2,228
1,916
1,805
1,041
607
17
19
19
15
22
10
10
3
4
2
1
0
0
0
3
3
4
233
156
466
863
683
1,699
1,6996838634661562334330001243101022151919176071,0411,8051,9162,2282,3262,52244928
       Goodwill 
0
0
0
0
0
1
1
1
1
0
4,987
4,648
4,307
0
0
0
0
0
0
0
961
0
0
0
0
0
0
0
0
0
0
0
0000000000096100000004,3074,6484,9870111100000
       Long Term Investments 
0
0
0
0
0
0
450
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20
20
50
81
115
252
218
2,413
2,4132182521158150202000000000000000000450000000
       Intangible Assets 
4,000
3,692
3,385
3,077
2,770
2,463
2,155
1,847
1,568
0
4,987
4,648
4,307
3,965
3,624
3,283
2,942
2,601
2,260
0
1,005
6,874
6,600
6,600
6,600
7,057
7,057
30,458
34,893
32,689
30,486
34,120
34,12030,48632,68934,89330,4587,0577,0576,6006,6006,6006,8741,00502,2602,6012,9423,2833,6243,9654,3074,6484,98701,5681,8472,1552,4632,7703,0773,3853,6924,000
       Long-term Assets Other 
73
566
4,000
2,330
2,770
550
450
-1
0
1
475
0
0
0
0
0
0
0
0
0
-1,965
-6,874
-6,600
-6,623
-6,623
-7,081
-7,340
16
16
35
19
133
13319351616-7,340-7,081-6,623-6,623-6,600-6,874-1,96500000000047510-14505502,7702,3304,00056673
> Total Liabilities 
587
127
1,305
1,127
1,241
1,136
898
903
2,667
52
701
584
412
806
561
493
437
307
480
245
698
1,899
1,383
1,679
1,283
1,439
3,485
5,399
6,791
8,901
7,437
33,143
33,1437,4378,9016,7915,3993,4851,4391,2831,6791,3831,899698245480307437493561806412584701522,6679038981,1361,2411,1271,305127587
   > Total Current Liabilities 
264
127
840
601
1,009
969
755
709
2,667
52
701
584
412
806
561
493
437
307
480
245
167
697
397
694
297
438
2,424
2,899
4,457
7,425
6,084
29,299
29,2996,0847,4254,4572,8992,424438297694397697167245480307437493561806412584701522,6677097559691,009601840127264
       Short-term Debt 
61
34
160
167
332
437
148
143
1,215
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
59
61
106
184
191
912
9121911841066159000000000000000001,2151431484373321671603461
       Short Long Term Debt 
0
0
0
0
0
0
241
286
1,215
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000001,215286241000000
       Accounts payable 
44
49
613
204
347
390
488
431
798
51
456
552
285
689
419
380
269
169
74
117
161
155
98
265
16
289
1,479
1,013
760
4,513
2,341
5,968
5,9682,3414,5137601,0131,479289162659815516111774169269380419689285552456517984314883903472046134944
       Other Current Liabilities 
41
78
-233
10
115
669
417
501
179
1
245
33
127
117
142
114
168
138
407
128
6
542
300
428
281
150
944
1,826
3,591
2,727
3,552
22,418
22,4183,5522,7273,5911,826944150281428300542612840713816811414211712733245117950141766911510-2337841
   > Long-term Liabilities 
323
0
465
526
232
167
143
194
0
0
0
0
0
0
0
0
0
0
0
0
531
1,202
985
985
985
1,001
1,061
2,499
2,334
1,476
1,353
3,845
3,8451,3531,4762,3342,4991,0611,0019859859851,2025310000000000001941431672325264650323
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
985
985
1,050
8
165
489
362
0
036248916581,050985985000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
50
52
0
0
0
0
0
0
0
0
0
0
0
0
531
1,202
985
985
985
1,001
997
2,491
2,169
987
991
0
09919872,1692,4919971,0019859859851,2025310000000000005250000000
> Total Stockholder Equity
5,111
11,186
10,621
8,122
7,452
6,755
5,995
2,779
-227
793
7,443
5,432
8,653
6,462
4,700
4,670
5,326
3,791
4,207
1,073
1,886
6,732
7,732
7,857
11,395
15,475
27,295
59,806
65,018
138,705
189,626
118,254
118,254189,626138,70565,01859,80627,29515,47511,3957,8577,7326,7321,8861,0734,2073,7915,3264,6704,7006,4628,6535,4327,443793-2272,7795,9956,7557,4528,12210,62111,1865,111
   Common Stock
4,665
9,115
9,585
10,628
12,162
14,364
24,352
25,556
26,714
28,516
36,751
8,165
13,180
13,180
13,180
14,907
14,907
14,907
14,907
14,907
17,280
24,237
27,652
30,407
36,335
44,286
63,122
92,798
113,107
230,789
314,402
370,313
370,313314,402230,789113,10792,79863,12244,28636,33530,40727,65224,23717,28014,90714,90714,90714,90714,90713,18013,18013,1808,16536,75128,51626,71425,55624,35214,36412,16210,6289,5859,1154,665
   Retained Earnings -289,832-141,436-103,521-65,652-47,310-36,817-29,110-26,143-23,647-20,916-18,476-16,360-14,800-11,667-12,082-10,547-11,197-9,286-6,982-4,527-2,733-29,308-27,963-29,802-25,761-21,341-16,411-11,865-9,683-5,439-3,304-2,429
   Accumulated Other Comprehensive Income 
2,875
5,375
6,475
7,177
7,885
9,532
2,984
2,984
2,861
240
-4
-11
-18
265
806
960
966
966
966
966
966
966
966
1,096
1,202
300
989
14,319
17,563
11,437
16,660
37,773
37,77316,66011,43717,56314,3199893001,2021,096966966966966966966966960806265-18-11-42402,8612,9842,9849,5327,8857,1776,4755,3752,875
   Capital Surplus 00000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000



5.4. Balance Sheets

Currency in AUD. All numbers in thousands.